Skip to content
Ecat.nl
Ecat.nl
Home
Docs
Parameter
Test Information
Test Information
4Ts Score for the diagnosis of HIT
An introduction to haemophilia
Antibodies against factor XIII subunits
Antibodies to blood coagulation factors; immunological background
Assay systems to measure platelet-dependent von Willebrand factor activity (GPIbα binding)
Clinical features of inhibitors in haemophilia A
Current classification, diagnosis and treatment of von Willebrand disease
Development of platelet function testing guidelines
Direct oral anticoagulants in atrial fibrillation
Direct Oral AntiCoagulants in Venous Thromboembolism
Factor XIII in thrombotic diseases
Flowcytometry for evaluation of platelet disorders
Future approaches to studying platelet function
Genetics of Factor XIII
Guideline for the treatment and prevention of HIT. A summary of the CHEST ACCP Guideline 9th edition.
Heparin-Induced Thrombocytopenia. Is there an alternative for unfractionated heparin?
Heparin, a short overview
Influence of Direct Oral AntiCoagulants on coagulation assays and the factors to consider for correctly interpreting tests
Inherited and acquired platelet function disorders
Inherited FXIII deficiency: clinical symptoms
Inhibitors against ADAMTS13
Inhibitors in mild or moderate hemophilia A
Laboratory measurement of Direct Oral AntiCoagulants (DOACs)
Laboratory measurement of extended half-life FIX concentrates
Laboratory measurement of extended half-life FVIII products
Laboratory monitoring of new hemostatic agents (Long-acting factor concentrates)
Management of bleeding complications in patients treated with Direct Oral AntiCoagulants
Measurement of factor VIII for the diagnosis of haemophilia A
Measurement of Factor VIII inhibitors: Detection, Improvement and Perspectives
Molecular testing for platelet function disorders
Monitoring antiplatelet therapy
New developments in the treatment of haemophilia
New developments in the treatment of haemophilia: implications for laboratory testing
Optimizing prophylactic treatment in haemophilia: when to use longer-acting products
Pathophysiology of heparin-induced thrombocytopenia
Patient-tailored therapy in haemophilia A: Towards pharmacokinetically guided dosing of factor VIII replacement therapy
Personalising therapy in haemophilia Pharmacokinetic-guided dosing of factor VIII and factor IX concentrates
Phenotype and genotype associations in von Willebrand disease
Platelet aggregometry/lumi-aggregometry
Platelet Transmission Electron Microscopy
Platelets in inflammation, infection and cancer
Potency labelling of extended half-life FVIII and FIX products
Quality Control for the Platelet Function Analyser (PFA)
Results of a workshop on the inter-laboratory variability of analysis of type 1 factor VIII Inhibitors
Role of gene therapy in the future treatment of haemophilia patients
The comparison between unfractionated heparin (UFH) versus low molecular weight heparin (LMWH) for avoiding HIT
The detection of Factor VIII Inhibitors with the Nijmegen assay
The do’s and don’ts of laboratory detection of haemostasis-inhibitors: lessons from a workshop
The future of haemophilia treatment: beyond the suppletion of factor VIII and IX
The genetic background of haemophilia
The ideal AntiCoagulant Drug
The Laboratory Diagnosis of HIT
The laboratory diagnosis of inherited FXIII deficiencies and the measurement of FXIII activity and antigen level
The measurement of Direct Oral AntiCoagulants in urine by a point-of-care test
The multimer analysis
The organization of thrombosis care
The role of Factor XIII in fibrin clot formation
The role of the clinical laboratory in the management of patients treated with Direct Oral AntiCoagulants
Type 2N von Willebrand disease: clinical, therapeutical and laboratory aspects
Update on platelet aggregation testing
Validation of methods in hemostasis testing: a practical approach
Von Willebrand Disease Testing Repertoire:The Past, Present and Future
Wet Workshop on Platelet Function Testing
Questions or suggestions?
Clotpedia Support Form
Submit
Success
